Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.
Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
First KRAS targeted therapy shows promise for lung and colon cancer
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
FDA says studies of new breast cancer treatments should allow enrollment of men as well as women.
Treatment involves selecting, multiplying and reinfusing cancer-fighting immune cells.
A three-pronged approach could offer hope for people with hard-to-treat advanced pancreatic cancer.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
New initiative will help health care providers navigate the process of submitting expanded access requests.
Nine organizations join forces to make clinical trial information available, paving the way for improved patient matching.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.